Investing.com - Mesoblast reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Mesoblast announced earnings per share of $-0.19 on revenue of $2.1M. Analysts polled by Investing.com anticipated EPS of $-0.145 on revenue of $3.16M.
Mesoblast shares are down 17% from the beginning of the year and are trading at $3.680 , down-from-52-week-high.They are under-performing the FTSE 100 which is up 1.69% from the start of the year.
Mesoblast follows other major Healthcare sector earnings this month
Mesoblast's report follows an earnings beat by UnitedHealth on April 14, who reported EPS of $5.49 on revenue of $80.15B, compared to forecasts EPS of $5.36 on revenue of $78.73B.
J&J had beat expectations on April 19 with first quarter EPS of $2.67 on revenue of $23.43B, compared to forecast for EPS of $2.59 on revenue of $23.62B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar